Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors

Trial Profile

Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Patritumab (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 13 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top